Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > LATEST
LATEST
-
REGULATORY 2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
-
BUSINESS Shionogi’s COVID Pill Hits Main Goal in PIII, Discussion on Regulatory Path to Follow
September 29, 2022
-
REGULATORY Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
-
BUSINESS Yakult Honsha Pulls NDA for Blood Cancer Med Duvelisib in Japan
September 29, 2022
-
BUSINESS Taisho Files Autoinjector Version of RA Med Nanozora in Japan
September 29, 2022
-
ORGANIZATION Generic Use Rate at 79.8% in April-June, Flat YOY: JGA
September 29, 2022
-
BUSINESS Maruishi/Kissei’s Pruritus Med Difelikefalin Filed in Japan
September 29, 2022
-
BUSINESS Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
-
BUSINESS Evusheld Can Fulfill Immunodeficient Patients’ Needs: AstraZeneca Japan VP
September 28, 2022
-
COMMENTARY Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
-
BUSINESS Sumitomo Appeals to US Court to Overturn Dismissal of Latuda’s Use Patent
September 28, 2022
-
BUSINESS Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
-
REGULATORY Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
-
REGULATORY MHLW’s Healthcare DX Promotion Team Holds 1st Meeting, Sets Up 2 Task Forces
September 27, 2022
-
BUSINESS Promotions via In-Hospital Seminars, Webinars, Internet Channels Log Two-Digit Growth in August: Intage
September 27, 2022
-
BUSINESS Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
-
BUSINESS Hospira Barred from Launching Lexiscan Generic until Oct. 5: Astellas
September 27, 2022
-
REGULATORY Keytruda Gets Label Update to Add Adjuvant Data for Melanoma
September 27, 2022
-
REGULATORY Discussions on FY2023 Drug Price Revision Method to Be Held by Chuikyo: Minister
September 26, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…